© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Mark Bloom
Articles
Physician Groups Press Congress to Override SCHIP Veto
October 03, 2007
WASHINGTON -- The AMA said it was "deeply disappointed" with President Bush's veto of the SCHIP reauthorization, and the American Academy of Pediatrics called the action "hurtful to children."
Human Thrombin Gets FDA Approval
August 28, 2007
ROCKVILLE, Md. -- The FDA today allowed a human thrombin (Evithrom) on the market after the risk of transfusion-transmitted viral infection kept it on the sidelines for more than a half-century.
Survey: Would you refer a patient overseas for treatment?
August 17, 2007
Take this MedPage Today survey on medical tourism.
FDA Reveals and Quells Concern Over Proton-Pump Inhibitors
August 09, 2007
ROCKVILLE, Md. -- After nine weeks of internal worry about the cardiovascular safety of two prescription proton-pump inhibitors, Prilosec and Nexium, the FDA has issued a limited all clear.
Chief Justice Roberts Suffers Seizure
July 30, 2007
ROCKPORT, Me. -- Chief Justice John Roberts had a benign idiopathic seizure today at his summer home near here and was hospitalized as a precaution, according to the Supreme Court.
Bush Adenomatous Polyps Determined Benign
July 23, 2007
WASHINGTON -- The White House said today that pathology on five adenomatous polyps discovered during a colonoscopy performed on President Bush over the weekend were all benign.
BREAKING NEWS: British Analysis Does Not Confirm Rosiglitazone (Avandia) MI Risk
June 05, 2007
NEWCASTLE UPON TYNE, England, June 5 -- An interim analysis of the 4,447-patient RECORD trial did not confirman increased risk of myocardial infarction or cardiac death in patients taking rosiglitazone (Avandia) for treatment of type 2 diabetes, although the data suggest an increased risk of heart failure. So reported the New England Journal of Medicine online today, one day before a Congressional hearing on the safety of rosiglitazone.
BREAKING NEWS: Meta-Analysis Finds Increased Risk of MI with Rosiglitazone (Avandia)
May 21, 2007
CLEVELAND -- A meta-analysis of 42 randomized trials released online by the New England Journal of Medicine today found a 43% increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small. A journal editorial says FDA action is warranted, and a congressional inquiry is expected.
ASCO Abstract Book May Covertly Reach Wall Street Insiders
May 18, 2007
NEW YORK -- The Wall Street Journal suggested today that the American Society of Clinical Oncology (ASCO) may be tempting its members to buy low or sell high, on the sly, by sending them advance confidential copies of its annual meeting abstract book.